(Q28215205)

2

0 references

Andreas Steinbrecher

3

0 references

Sabine Wrenger

4

0 references

Klaus Neubert

5

0 references

Siegfried Ansorge

6

0 references

Stefan Brocke

CD26, let it cut or cut it down.

7

0 references

language of work or name

English

0 references

publication date

2002

1 reference

0 references

383

0 references

issue

7-8

0 references

page(s)

1133-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

CD26: a surface protease involved in T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

Direct association of adenosine deaminase with a T cell activation antigen, CD26

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123

Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2002.123